CN110709103B - 用于生物学样品中具有改善的性能的timp2的测定法 - Google Patents

用于生物学样品中具有改善的性能的timp2的测定法 Download PDF

Info

Publication number
CN110709103B
CN110709103B CN201880034638.3A CN201880034638A CN110709103B CN 110709103 B CN110709103 B CN 110709103B CN 201880034638 A CN201880034638 A CN 201880034638A CN 110709103 B CN110709103 B CN 110709103B
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
acid sequence
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880034638.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110709103A (zh
Inventor
R·A·维杰耶德兰
S·文卡巴苏巴拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smart Medicine Co ltd
Original Assignee
Smart Medicine Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smart Medicine Co ltd filed Critical Smart Medicine Co ltd
Publication of CN110709103A publication Critical patent/CN110709103A/zh
Application granted granted Critical
Publication of CN110709103B publication Critical patent/CN110709103B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201880034638.3A 2017-04-05 2018-04-04 用于生物学样品中具有改善的性能的timp2的测定法 Active CN110709103B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482089P 2017-04-05 2017-04-05
US62/482,089 2017-04-05
PCT/US2018/026058 WO2018187453A1 (en) 2017-04-05 2018-04-04 Assays for timp2 having improved performance in biological samples

Publications (2)

Publication Number Publication Date
CN110709103A CN110709103A (zh) 2020-01-17
CN110709103B true CN110709103B (zh) 2024-02-02

Family

ID=63712349

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880034638.3A Active CN110709103B (zh) 2017-04-05 2018-04-04 用于生物学样品中具有改善的性能的timp2的测定法

Country Status (5)

Country Link
US (2) US11718682B2 (cg-RX-API-DMAC7.html)
EP (1) EP3606554A4 (cg-RX-API-DMAC7.html)
JP (2) JP7315466B2 (cg-RX-API-DMAC7.html)
CN (1) CN110709103B (cg-RX-API-DMAC7.html)
WO (1) WO2018187453A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048346A1 (en) 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル,インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CN110007084B (zh) 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
CN110431422A (zh) 2017-02-06 2019-11-08 机敏医药股份有限公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2018187453A1 (en) 2017-04-05 2018-10-11 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
WO2023225626A2 (en) * 2022-05-20 2023-11-23 Adanate, Inc. Multi-targeting lilrb antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781471A (zh) * 2009-10-16 2012-11-14 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
CN105026429A (zh) * 2012-08-21 2015-11-04 美国政府(由卫生和人类服务部的部长所代表) 间皮素结构域-特异性单克隆抗体及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5698671A (en) 1989-03-21 1997-12-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metalloproteinase peptides
JP3156082B2 (ja) * 1989-03-21 2001-04-16 アメリカ合衆国 マトリックスメタロプロテイナーゼ阻害剤ペプチド
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP3017591B2 (ja) 1992-01-17 2000-03-13 富士薬品工業株式会社 抗ヒトtimp−2モノクローナル抗体の製法およびその利用
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6391265B1 (en) 1996-08-26 2002-05-21 Biosite Diagnostics, Inc. Devices incorporating filters for filtering fluid samples
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6045899A (en) 1996-12-12 2000-04-04 Usf Filtration & Separations Group, Inc. Highly assymetric, hydrophilic, microfiltration membranes having large pore diameters
DE69837544T2 (de) 1997-07-16 2007-12-20 Charm Sciences, Inc., Lawrence Testgerät und methode zur entdeckung von analyten in proben
JP2002507725A (ja) 1998-03-16 2002-03-12 クイデル コーポレイション イムノアッセイデバイスおよび方法
US7214542B2 (en) 2003-01-30 2007-05-08 Michael Hutchinson Method of processing assay test results
WO2004096832A2 (en) 2003-04-29 2004-11-11 Children's Medical Center Corporation Novel antiangiogenic peptides
US20070031286A1 (en) 2003-08-11 2007-02-08 Kyowa Medex Co., Ltd. Tool for measuring object to be measured, measuring device, and measuring method
EP1774338B1 (en) 2004-07-28 2009-06-03 F.Hoffmann-La Roche Ag Timp-2 as target/marker of beta cell failure
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2007048100A2 (en) 2005-10-18 2007-04-26 The Government Of The United States, As Represented By The Secretary Of Health & Human Services Angio-inhibitory peptides derived from human timp-2
WO2010048346A1 (en) 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8900881B2 (en) 2008-12-30 2014-12-02 Jin Po Lee Quantitative analyte assay device and method
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
CN102791885B (zh) 2010-02-05 2015-09-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
WO2011125877A1 (ja) 2010-03-31 2011-10-13 積水メディカル株式会社 イムノクロマトグラフィーを利用した測定方法、イムノクロマトグラフィー用テストストリップ及びイムノクロマトグラフィー用測定試薬キット
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2810825A1 (en) 2010-09-30 2012-04-05 Yoshiro Niitsu Modulation of timp1 and timp2 expression
CA2846602A1 (en) 2011-08-26 2013-03-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
WO2013158274A1 (en) 2012-04-20 2013-10-24 Academia Sinica ANTI-MIGE ANTIBODIES THAT BIND TO THE JUNCTION BETWEEN CH4 AND CεMX DOMAINS
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル,インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
WO2014197729A1 (en) 2013-06-05 2014-12-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20160039682A (ko) * 2013-08-07 2016-04-11 아스튜트 메디컬 인코포레이티드 생물학적 샘플에서 개선된 성능을 가지는 timp2에 대한 검정
AU2014346695B2 (en) 2013-11-06 2020-10-15 Astute Medical, Inc. Assays for IGFBP7 having improved performance in biological samples
CN110007084B (zh) 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
KR101605421B1 (ko) 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
GB201505314D0 (en) 2015-03-27 2015-05-13 Victrex Mfg Ltd Polymeric materials
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
EP3532101B1 (en) 2016-10-28 2021-12-08 Astute Medical, Inc. Use of antibodies to timp-2 for the improvement of renal function
CN110431422A (zh) 2017-02-06 2019-11-08 机敏医药股份有限公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2018187453A1 (en) 2017-04-05 2018-10-11 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
WO2018208684A1 (en) 2017-05-07 2018-11-15 Astute Medical, Inc. Use of insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 in the management of renal replacement therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781471A (zh) * 2009-10-16 2012-11-14 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
CN105026429A (zh) * 2012-08-21 2015-11-04 美国政府(由卫生和人类服务部的部长所代表) 间皮素结构域-特异性单克隆抗体及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"单克隆抗体双抗体夹心 ELISA 快速检测肝炎患者血清中 TIMP-2";聂青和等;《胃肠病学和肝病学杂志》;第第14卷卷(第第14卷期);第577-580页 *

Also Published As

Publication number Publication date
JP2020516603A (ja) 2020-06-11
JP7315466B2 (ja) 2023-07-26
US20240002529A1 (en) 2024-01-04
US20200071416A1 (en) 2020-03-05
EP3606554A1 (en) 2020-02-12
CN110709103A (zh) 2020-01-17
EP3606554A4 (en) 2020-12-09
US12624121B2 (en) 2026-05-12
WO2018187453A1 (en) 2018-10-11
US11718682B2 (en) 2023-08-08
JP2023145528A (ja) 2023-10-11

Similar Documents

Publication Publication Date Title
US12624121B2 (en) Assays for TIMP2 having improved performance in biological samples
US10562961B2 (en) Assays for IGFBP7 having improved performance in biological samples
US10457744B2 (en) Assays for TIMP2 having improved performance in biological samples
US20240124569A1 (en) Antibodies and assays for ccl14
CN114341178B (zh) Ccl14的抗体和检测

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20380611

TG01 Patent term adjustment